de Csepel J, Goldfarb B, Shapsis A, Goff S, Gabriel N, Eng H M
Department of Surgery, St. Vincent's Hospital, 170 West 12 Street, New York, NY 10011, USA.
Surg Endosc. 2006 Feb;20(2):302-6. doi: 10.1007/s00464-005-0119-4. Epub 2005 Dec 9.
Gastroparesis is a disabling, and sometimes fatal, disease that often does not respond to medical treatment. This single-surgeon prospective study examines the safety and 6-month efficacy of electrical stimulation for the treatment of gastroparesis.
Sixteen patients with medically refractory gastroparesis underwent laparoscopic implantation of an electrical stimulator device (Enterra Therapy, Medtronic, Minneapolis, MN, USA) consisting of a subcutaneous stimulator and two gastric wall leads. Gastric emptying scans (GES) confirmed the diagnosis of gastroparesis. Patients were evaluated preoperatively using a self-administered GI symptomatology questionnaire and RAND 36 Health Survey. Once patients were >6-months from implantation, a repeat GES was obtained and patients completed a postoperative GI symptomatology questionnaire and RAND 36 Health Survey. Ten of 16 patients in this case series were >6-months from implantation. One was lost to follow-up. An F-test was used to establish equality of standard deviations between the 16 patients evaluated preoperatively and the subset of 10 patients evaluated postoperatively. A Student's t-test was used to evaluate the significance of differences in pre- and postoperative results.
Average operating time was 117 min with no intraoperative complications. The majority of patients were discharged on postoperative day 1. There were two complications in the postoperative period. Patients experienced a significant decrease in nausea and vomiting as measured by the GI symptomatology questionnaire. Half of all patients no longer required gastric prokinetic medications and there was a subjective reduction of pyrosis, early satiety, and epigastric pain. A significant increase in quality of life as measured by the RAND 36 Health Survey was seen, and six of eight patients no longer demonstrated gastroparesis on GES.
Laparoscopic implantation of an electrical stimulation device is a safe and effective treatment by subjective and objective standards for the management of medically refractory gastroparesis.
胃轻瘫是一种致残甚至有时会致命的疾病,通常对药物治疗无反应。这项单外科医生前瞻性研究探讨了电刺激治疗胃轻瘫的安全性及6个月疗效。
16例药物难治性胃轻瘫患者接受了腹腔镜下植入电刺激装置(Enterra疗法,美敦力公司,美国明尼阿波利斯,MN),该装置由皮下刺激器和两根胃壁电极组成。胃排空扫描(GES)确诊为胃轻瘫。术前使用自我管理的胃肠道症状问卷和兰德36健康调查对患者进行评估。一旦患者植入后超过6个月,再次进行GES检查,并让患者完成术后胃肠道症状问卷和兰德36健康调查。该病例系列中的16例患者中有10例植入后超过6个月。1例失访。使用F检验确定术前评估的16例患者与术后评估的10例患者子集之间标准差的相等性。使用学生t检验评估术前和术后结果差异的显著性。
平均手术时间为117分钟,无术中并发症。大多数患者术后第1天出院。术后有2例并发症。根据胃肠道症状问卷测量,患者的恶心和呕吐显著减少。所有患者中有一半不再需要胃动力药物,烧心、早饱感和上腹部疼痛主观上有所减轻。通过兰德36健康调查测量,生活质量显著提高,8例患者中有6例在GES检查中不再显示胃轻瘫。
根据主观和客观标准,腹腔镜植入电刺激装置是治疗药物难治性胃轻瘫的一种安全有效的方法。